Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
|
|
- Constance Cain
- 5 years ago
- Views:
Transcription
1 CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita, MD, PhD; Niro Okimoto, MD, PhD; Toshiharu Matsushima, MD, PhD; Takeshi Kageoka, MD, PhD; and Mikio Oka, MD, PhD Original Research TUBERCULOSIS Objective: To evaluate the response to the QuantiFERON--2 Gold (QFT-2G) test (Cellestis Ltd; Carnegie, VIC, Australia) in elderly patients with active tuberculosis () to determine whether the QFT-2G test might be a feasible method for diagnosing infection in this group of patients. Methods: The subjects were 30 elderly patients with active and 00 younger patients with active. The QFT-2G test results were analyzed in relation to combined and separate responses to early secretory antigenic target 6-kD (ESAT-6) protein and culture filtrate protein 0 (CFP-0) antigens. Results: Of the 30 elderly patients with active, 27% had a positive tuberculin skin test (TST) result and 77% had a positive QFT-2G test result. Of the 00 younger patients with active, 70% had a positive TST result and 87% had a positive QFT-2G test result. Although there was no significant difference between the two patient groups in the positive rate for the QFT-2G test results (p 0.85), there was a significant difference in the rates of positive TST results between the elderly and younger patients (p 0.02). The positive test result rate for both ESAT-6 and CFP-0 antigens in the elderly patients (7%) was significantly lower than that in younger patients (37%; p 0.038). There was an indeterminate result for the QFT-2G test in five elderly patients, and this might have been related to the presence of lymphocytopenia due to underlying disease. A negative result on the QFT-2G test was detected in two elderly patients, and this might have been related to the severity of the active. Conclusion: We confirmed that the QFT-2G test might be a more useful method of diagnosing infection than the TST for elderly patients if peripheral lymphocyte counts have been preserved. (CHEST 2008; 33:96 202) Key words: active tuberculosis; elderly patients; QuantiFERON -2G; tuberculin skin test Abbreviations: BCG bacillus Calmette-Guerin; CFP-0 culture filtrate protein 0; ESAT-6 early secretory antigenic target 6-kd; IFN interferon; M Mycobacterium tuberculosis; QFT-2G QuantiFERON--2 Gold; tuberculosis; TST tuberculin skin test Although the tuberculin skin test (TST) has frequently been performed as the standard immunologic diagnostic tool for diagnosing tuberculosis () infection in the 20th century, it does not reliably distinguish resulting either from previous immunization with the bacillus Calmette-Guerin (BCG) vaccine or from most nontuberculous mycobacteria. To replace the TST test, the availability of Mycobacterium tuberculosis (M) antigen-specific interferon (IFN)- release assays has represented a significant advance in the field of diagnosis. 2 4 These assays measure T-cell-induced IFN- responses in M-specific peptides derived from the early secretory antigenic target 6-kD (ESAT-6) protein and culture filtrate protein 0 (CFP-0). These antigens are encoded by the genetic region of difference that is present in all strains of M but is absent in nontuberculous mycobacteria and all BCG vaccine strains. The following two commercial IFN- assays have become available in the last few years: the QuantiFERON--2 Gold (QFT-2G) assay (Cellestis Ltd; Carnegie, VIC, Australia) with an enzyme-linked immunosorbent assay used to mea- 96 Original Research
2 sure IFN- concentrations in supernatants; and T-SPOT. (Oxford Immunotec; Oxon, UK) with an enzyme-linked immunospot assay used to detect individual T cells producing IFN-. 5,6 The US Food and Drug Administration has approved the QFT-2G test and is currently evaluating the T-SPOT. test, which has been approved for use in Europe. These tests demonstrate a positive result for most persons with active disease. Of these tests, although the QFT-2G test was first used commercially in Japan in April 2005 for the diagnosis of, the T-SPOT. test has not yet been approved in Japan. Therefore, we performed the QFT-2G test for elderly patients with active and compared findings with those of the TST test in this study. To date, although there have been many reports 7 0 about the clinical usefulness of the QFT-2G test for patients with infection or latent infection, it has been indicated that care is needed when diagnosing infection for young pediatric patients (ie, those 5 years old) or elderly patients. However, there have been few studies performing a detailed investigation of the clinical effectiveness for elderly patients (ie, those 80 years old) with active. Therefore, we evaluated the QFT-2G test responses in elderly patients with active to determine whether the QFT-2G test might be a feasible method for diagnosing infection in elderly patients (ie, those 80 years old) compared to that in younger patients (ie, those 80 years old) according to the combined and separate responses to ESAT-6 and CFP-0 antigens. Study Population Materials and Methods One hundred thirty patients including 30 elderly patients with active that had been confirmed by positive results of cultures *From the Division of Respiratory Diseases (Drs. Kobashi, Mouri, Yagi, Obase, Miyashita, and Oka), Department of Medicine, Kawasaki Medical School, Kurashiki, Japan; the Division of Respiratory Diseases (Dr. Okimoto), Department of Medicine, Kawasaki Medical School Kawasaki Hospital, Okayama, Japan; the Division of Respiratory Diseases (Dr. Matsushima), Kurashiki Daiichi Hospital, Oimatsuchou, Kurashiki, Japan; and the Department of Laboratory Division, Kurashiki Central Hospital, Kurashiki, Japan. The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Manuscript received August 7, 2007; revision accepted July 5, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Yoshihiro Kobashi, Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, , Japan; yoshihiro@med. kawasaki-m.ac.jp DOI: 0.378/chest of sputum, BAL fluid, pleural fluid, peritoneal fluid, or lymph node tissue samples were prospectively enrolled between April 2005 and June This study was approved by the ethics committee of each institution. The patients with active received their diagnoses at Kawasaki Medical School Hospital (,072 beds), Kawasaki Medical School Kawasaki Hospital (650 beds), Kurashiki Central Hospital (,570 beds), Kurashiki Daiichi Hospital (92 beds), or Asahigaoka Hospital (90 beds). We obtained written, informed consent from all patients in this study. All patients had either negative responses to serological tests for HIV or had no obvious risk factors for HIV infection. Subjects were divided into the following two groups: group consisted of 30 elderly patients ( 80 years old) with active ; and group 2 consisted of the remaining 00 younger patients ( 80 years old) with active. From patients in both groups with active, we collected demographic data regarding () any history of previous infection or antituberculous treatment, (2) other underlying diseases (ie, respiratory diseases such as healed pulmonary or COPD, and nonrespiratory diseases such as malignant disease, including leukemia, diabetes mellitus, renal failure with hemodialysis, collagen vascular disease, neurologic disease, GI disease, cardiovascular disease, and HIV infection), and (3) the receipt of immunosuppressive drugs within 3 months before enrollment into this study. Information regarding any previous Mantoux TST results and BCG vaccination inoculation, as well as information about laboratory findings (ie, WBC count, lymphocyte count, total protein concentration, and albumin concentration) and radiologic findings (ie, portion, extension, and cavity) were collected at the time of enrollment. Sputum or other appropriate respiratory samples were collected from all patients, and culture samples were obtained for the detection of mycobacteria. Sample Collection and TST Each patient in both groups had a heparinized blood sample collected by venipuncture for performing a whole-blood IFN- assay. Blood samples were collected before the administration of the Mantoux TST. For the TST test, 0. ml of tuberculin purified protein derivative (Nippon BCG Manufacturing; Tokyo, Japan [equivalent to three tuberculin units of purified protein derivative solution]) was injected intradermally into the volar aspect of the forearm, and the transverse induration diameter was measured 48 h later. The results of the test were interpreted by hospital staff based on the patient s degree of risk, according to current guidelines ; a lower cutoff of 5 mm for a positive test result was used for each patient. QFT-2G Test The QFT-2G test was performed according to the recommendations of the manufacturer, and the test result was judged according to the guidelines of the Centers for Disease Control and Prevention. 5 In brief, the test consisted of a negative control (a nil well [ie, whole blood without antigens or mitogen]), a positive control (a mitogen well [ie, whole blood stimulated with the mitogen phytohemagglutinin]), and two sample wells (ie, whole blood stimulated with either ESAT-6 or CFP-0). Wholeblood specimens were incubated for 8 h (overnight) at 37 C in a humidified atmosphere. The IFN- level of the nil well was considered to be the background value and subtracted from the values for the mitogen well and the antigen-stimulated wells. The test result was considered to be positive if the IFN- level in the sample well after stimulation with ESAT-6, and after the CFP-0 concentration was 0.35 IU/mL (after subtraction of the value for the nil well), irrespective of the result for the positive control well. The test was considered to be negative if CHEST / 33 / 5/ MAY,
3 the IFN- level was 0.35 IU/mL and the IFN- level of the positive control well was 0.5 IU/mL. The test result was considered to be indeterminate if the IFN- level was 0.35 IU/mL in both antigen wells and 0.5 IU/mL in the positive control well. Statistical Analysis Information from the questionnaires, TST results, and wholeblood IFN- assay results were entered into spread sheet software (Excel 2000; Microsoft; Redmond, WA) and then were transferred to a statistical software package (Stata, version 7.0 Stata Corp; College Station, TX) for statistical analysis. The Pearson 2 test was used to compare proportions in the two groups, and the McNemar test was used to compare paired proportions. The Mann-Whitney U test was used to compare unpaired results, and the Wilcoxon signed rank test was used to compare paired observations. Significance was recognized at p Results Thirty elderly patients (ie, those 80 years old) with active (group ) and 00 younger patients (ie, those 80 years old) with active (group 2) were enrolled into this study between April 2005 and June The clinical diagnosis of the group patients was pulmonary in 22 patients (including pulmonary tuberculoma in 2 patients), tuberculous pleuritis in 4 patients, miliary in 2 patients, tuberculous lymphadenitis in patient, and pulmonary plus tuberculous pleuritis in patient. The clinical diagnosis of the patients in group 2 was pulmonary in 59 patients (including pulmonary tuberculoma in 8 patients), tuberculous pleuritis in 4 patients, tuberculous lymphadenitis in 2 patients, pulmonary and tuberculous pleuritis in 8 patients, miliary in 5 patients, and tuberculous peritonitis in 2 patients. There was no significant difference in the clinical diagnoses between the two groups. Thirty patients in group were confirmed as being positive for M by cultures of samples of sputum (3 patients with pulmonary and patient with pulmonary tuberculoma), BAL fluid (7 patients with pulmonary, 2 patients with miliary, and patient with pulmonary tuberculoma), pleural fluid (4 patients with tuberculous pleuritis and patient with pulmonary and tuberculous pleuritis), resected lymph node ( patient with cervical tuberculous lymphadenitis). Acid-fast smear results for sputum, bone marrow, BAL fluid, pleural or peritoneal fluid, or lymph node samples were positive in 4 of 30 patients (47%) in group. The remaining 6 patients had negative results for acidfast smear and positive results for cultures for. One hundred patients in group 2 were confirmed as being positive for M by cultures of samples of sputum (32 patients with pulmonary, 6 patients with pulmonary and tuberculous pleuritis, and 2 patients with pulmonary tuberculoma), BAL fluid (9 patients with pulmonary, 6 patients with pulmonary tuberculoma, and 5 patients with miliary ), pleural fluid (4 patients with tuberculous pleuritis and 2 patients with pulmonary and tuberculous pleuritis), resected lymph node (2 patients with cervical tuberculous lymphadenitis), peritoneal fluid (2 patients with tuberculous peritonitis). Acid-fast smear results for samples were positive in 54 of 00 patients (54%) in group 2. The remaining 46 patients had negative acid-fast smear results and positive culture results for. The clinical characteristics of both groups are shown in Table. Compared to group 2, group had Table Clinical Characteristics of 30 Elderly Patients ( ) and 00 Younger Patients ( 2)* (n 30) 2 (n 00) Clinical Characteristics Pulmonary (n 22) Extrapulmonary (n 8) Both (n 30) Pulmonary (n 59) Extrapulmonary (n 4) Both (n 00) p Value Age, yr Sex Male Female Smoking history 5 (68) 6 (75) 2 (70) 38 (64) 26 (63) 64 (64) Alcohol abuse history 4 (8) (3) 5 (7) (9) 7 (7) 8 (8) 0.95 Underlying disease 22 (00) 8 (00) 30 (00) 39 (66) 25 (6) 64 (64) 0.03 Respiratory disease 9 (4) 3 (38) 2 (40) 8 (3) 3 (32) 3 (3) 0.93 Nonrespiratory disease 3 (59) 5 (62) 8 (60) 2 (35) 2 (29) 33 (33) Immunosuppressive treatment 2 (9) (3) 3 (0) 6 (0) 4 (0) 0 (0) Received BCG vaccination 3 (59) 5 (63) 8 (60) 37 (63) 24 (59) 6 (6) Received treatment 4 (8) 2 (25) 6 (20) 0 (7) 6 (5) 6 (6) 0.86 *Values are given as the mean SD or No. (%), unless otherwise indicated. All patients received corticosteroid therapy. 98 Original Research
4 Table 2 Comparison Between the Results of TST and QFT-2G Test Among 30 Elderly Patients With Active Disease ( ) and 00 Younger Patients With Active Disease ( 2)* QFT-2G Test Result TST Result Positive Negative Total Positive Negative Indeterminate Total *Values are given as %. Table 4 Comparison of the Results of QFT-2G Test Analyzed by Combined and Separate Responses to ESAT-6 and CFP-0 Antigens Between Elderly Patients ( ) and 00 Younger Patients ( 2)* QFT-2G Test (n 30) 2 (n 00) Total (n 30) p Value ESAT-6 protein 0 (33) 28 (28) 38 (29) 0.08 only positive CFP-0 only 9 (30) 27 (27) 36 (28) positive ESAT-6 protein and 4 (3) 32 (32) 36 (28) CFP-0 positive Total 23 (77) 87 (87) 0 (85) *Values are given as No. (%), unless otherwise indicated. a significantly higher percentage of patients with underlying disease, especially nonrespiratory disease. Concerning the laboratory data and chest radiologic findings in the two groups, there were no significant differences in the indicators of immune status, such as peripheral lymphocyte counts or albumin concentrations, nutritional condition, extension of the lesion, or the existence of a cavity. Comparisons between the results of the TST and the QFT-2G test among 30 elderly patients and 00 younger patients with active are shown in Table 2. Elderly patients with active had a significantly higher rate of positive QFT-2G test results (76%) than of positive TST results (27%). However, younger patients with active did not show any significant difference between the positive rate on QFT-2G test results (87%) and the positive rate on TST results (70%). A comparison of the results of the TST and QFT-2G test, including the range and median of the maximum diameter of induration of the TST or those of IFN- levels of the QFT-2G test between elderly patients and younger patients, is shown in Table 3. Although group had a significantly lower positive result rate (27%) and lower values for positive results than group 2 (70%) on the TST test, there was no significant difference in the positive rate and the values for positive results on QFT-2G test between group (76%) and group 2 (87%). As for the QFT-2G test, negative findings were more frequent in group (two patients; 7%) than in group 2 (four patients; 4%), but there was no significant difference. The indeterminate result also occurred more frequently in group (five patients; 6%) than in group 2 (nine patients; 9%), but there was no significant difference. A comparison of QFT-2G test results that were analyzed according to the combined and separate responses to ESAT-6 and CFP-0 antigens between the elderly patient group (group ) and the group of 00 younger patients (group 2) is shown in Table 4. Although there was no significant difference in the rate of positive response to ESAT-6 protein antigen only (p 0.08) or CFP-0 antigen only (p 0.740) between the two groups, the positive response rate to ESAT-6 protein and CFP-0 antigens in group (3%) was significantly lower than that in group 2 (32%; p 0.038). The clinical findings of elderly patients with active who had false-negative or indeterminate Table 3 Comparison of the Results of TST and QFT-2G Test Between 30 Elderly Patients ( ) and 00 Younger Patients ( 2)* Test Results (n 30) 2 (n 00) Total (n 30) p Value TST Positive 8 (27) approximately 5 30 mm; 2 mm 70 (70) approximately 5 65 mm; 25 mm 78 (60) 0.02 (0.04) Negative 22 (73) 30 (30) 52 (40) 0.03 QFT-2G test Positive 23 (77) approximately IU/mL; 87 (87) approximately IU/mL; 0 (85) 0.85 (0.64).03 IU/mL.20 IU/mL Negative 2 (7) 4 (4) 6 (5) 0.44 Indeterminate 5 (7) 9 (9) 4 (0) 0.02 *Values are given as No. (%) range; median, unless otherwise indicated. Values in parenthesis are for comparisons of the positive response rates. CHEST / 33 / 5/ MAY,
5 QFT-2G test results are shown in Table 5. Although two patients showed false-negative results on the QFT-2G test as well as on the TST, these were both immunocompromised patients with severe underlying disease, and lymphocytopenia was recognized in the peripheral blood of these patients, although nutritional conditions such as total protein or albumin level were comparatively preserved. In one case, the sputum specimen was smear negative and culture positive ( colony at 8 weeks) for on bacteriologic findings, and showed slight extension of the lesion without cavity on radiologic findings. In the other case, pleural effusion was smear negative and culture positive ( colony at 8 weeks) for on bacteriologic findings, and tuberculous pleuritis was diagnosed. While five patients showed indeterminate results on the QFT-2G test, these five also had various underlying diseases, and lymphocytopenia was recognized in the peripheral blood of these patients. Furthermore, nutritional conditions were extremely poor in most of these patients. However, all five patients showed negative results on serologic tests for HIV. Regarding the judgment of the QFT-2G test, two patients were considered to have had negative responses because the positive control of the QFT-2G test was 0.5 IU/mL. Five patients were considered to have indeterminate results because the positive control for the QFT-2G test was 0.5 IU/mL. Otherwise, four patients in group 2 showed negative results on the QFT-2G test due to severe underlying diseases and lymphocytopenia, as well as negative results on the TST (the positive control of the QFT-2G test was 0.5 IU/mL). Nine patients in group 2 showed indeterminate results on the QFT-2G test due to various underlying diseases and lymphocytopenia, as well as negative results on the TST (the positive control for the QFT-2G test was 0.5 IU/mL). Discussion Whereas the sensitivity of the QFT-2G test for detecting infection in patients with untreated culture-confirmed was approximately 80% in previous studies, 7,9 its sensitivity for detecting infection in younger pediatric patients ( 5 years old), elderly patients, or immunocompromised patients has not yet been determined. Recently, Detjen et al 2 reported that IFN- release assays (both the QFT-2G and T-SPOT. tests) are useful for diagnosing disease in young children. Luetkemeyer et al 3 and Rangaka et al 4 reported that these assays were useful tests for diagnosing in immunocompromised patients with HIV infection. However, there have been few reports investigating in detail Table 5 Clinical Findings of Elderly Patients With Active Disease Who Had False-Negative or Indeterminate QFT-2G Test Results* Clinical Diagnosis Chest Radiograph Finding AFB Smear Result/ Culture Result (Culture Specimen) TST Result HIV Status Lymphocyte Count, cells/ L WBC Count, cells/ L Alb, mg/dl TP, mg/dl Underlying Disease Age, yr/sex QFT-2G Test Result Patient No , / (Sputum) Right cavity ( ) Pulmonary Negative 82/M Rheumatoid lung , / (PE) Left PE Tuberculous pleuritis 2 Negative 80/M Diabetes mellitus Pulmonary , / (Sputum) Bilateral cavity ( ) 3 Indeterminate 89/M Lung cancer Pulmonary 4 Indeterminate 85/F CVD , / (BALF) Bilateral cavity ( ) 5 Indeterminate 83/M MDS , / (Sputum) Left cavity ( ) Pulmonary 6 Indeterminate 80/M Gastric , / (BALF) Right cavity ( ) Pulmonary ulcer 7 Indeterminate 87/M OMI , / (Sputum) Bilateral Pulmonary cavity ( ) *AFB acid-fast bacilli; BALF BAL fluid; CVD cerebrovascular disease; MDS myelodysplastic syndrome; PE pleural effusion; F female; M male; negative; positive; TP total protein; Alb albumin. Data denote portion and cavity finding. Treated with corticosteroid therapy. 200 Original Research
6 the clinical usefulness of these tests for elderly patients (ie, those 80 years old) with active. Concerning the QFT-2G test result and the TST result stratified by age, Mori et al 7 reported that while the positive result rates on the QFT-2G test and the TST were 92.3% and 54.5%, respectively, for 3 and patients (approximately 7 to 80 years old), those on the QFT-2G test and the TST were 80.0% and 6.7%, respectively, for 0 and 6 elderly patients (ie, those 80 years old). That is, the positive result rate on the TST was strikingly decreased in elderly patients with active who were 80 years old. Concerning this finding, we investigated the usefulness of the QFT-2G test as a supportive method for diagnosing infection in elderly patients (ie, those 80 years old) compared to that in younger patients ( 80 years old) in this study. Subsequently, although 27% of elderly patients with active had a positive TST result and 77% of this group had a positive QFT-2G result, and there was a significant difference between the results of the TST and THE QFT-2G test, 70% of younger patients with active had a positive TST result and 87% had a positive QFT-2G test result. Furthermore, there was no significant difference between TST test and QFT-2G test results in younger patients. Our findings resembled those reported by Mori et al. 7 This study confirmed that the QFT-2G test is a useful method for diagnosing infection compared to the TST even for elderly patients (ie, those 80 years old). Concerning the combined and separate responses to ESAT-6 protein and CFP-0 antigens in the QFT-2G test, the positive rate for response to both ESAT-6 protein and CFP-0 antigens in elderly patients with active was significantly lower than that in younger patients with active. Chee et al 5 reported that 47% of patients were positive for CFP-0 only, 20% of patients were positive for ESAT-6 protein only, and 33% of patients were positive for both antigens when the results were analyzed using combined and separate responses to ESAT-6 protein and CFP-0 antigens in 226 adults suspected of having latent infection by results of the T-SPOT. assay. The roles of ESAT-6 protein and CFP-0 in pathogenesis have not been yet defined. The genes encoding these antigens are transcribed together 6 ; these two proteins form a tight : complex, and evidence suggests that they are active as a complex. 7 As the reason underlying the low positive response rate for both antigens, it may be speculated that the dose of IFN- produced by M-specific antigens such as those for ESAT-6 protein and/or CFP-0 gradually decreases with aging. However, although we adopted the Centers for Disease Control and Prevention guidelines 5 for cutoff values indicating a positive response on the QFT-2G test (ie, levels of either ESAT-6 protein or CFP-0 antigen of 0.35 IU/mL), there was no problem in judging the results of QFT-2G tests for elderly patients with active because the positive rate on the QFT-2G test was significantly higher than that on the TST. Next, we investigated the reason for indeterminate QFT-2G test results in five patients with active and the false-negative QFT-2G test results for two patients with active as well as negative TST results in elderly patients with active. This finding was the same in younger patients with active. These results may become parameters that are linked with negative results on the TST in both groups. All five patients with indeterminate QFT-2G test results showed severe lymphocytopenia (ie, peripheral lymphocyte counts of 500/ L) due to underlying diseases or aging (Table 5). This QFT-2G test depends on the elaboration of inflammatory cytokines by T cells previously sensitized to Mspecific antigens. In this test, mononuclear cells from peripheral blood are stimulated in vitro, and the production of IFN- from sensitized T cells is measured by the enzyme-linked immunosorbent assay method. 2 Therefore, we considered that lymphocytopenia caused a decrease in the production of IFN- and lower mitogen QFT-2G test levels (ie, 0.5 IU/mL). Although there were two patients showing negative QFT-2G results, these patients both showed mild lymphocytopenia (ie, peripheral lymphocyte counts of approximately 300 to 600 IU/mL), differing from the five patients with indeterminate responses to the QFT-2G test. We speculate that the reason for the negative response to the QFT-2G test mainly related to the limited dose of M in the sputum culture, the small lesion size, or the presence of tuberculous pleuritis as extrapulmonary rather than lymphocytopenia. In conclusion, this study demonstrated the usefulness of the QFT-2G test as an immunologic diagnostic method for the detection of elderly patients (ie, those 80 years old) with active compared with the TST. However, because several indeterminate QFT-2G test results were encountered among patients with active who demonstrated moderateto-severe lymphocytopenia due to underlying diseases and a few negative QFT-2G test results were encountered in patients with active showing a limited dose of M in the sputum culture, small lesion size, or the presence of tuberculous pleuritis as extrapulmonary, we must take care to identify such patients among elderly patients (ie, those 80 years old) at the time the QFT-2G test is performed in order to obtain an accurate diagnosis of active. CHEST / 33 / 5/ MAY,
7 References Huebner RE, Scheun MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 993; 7: Andersen P, Munk ME, Pollock JM, et al. Specific immunebased diagnosis of tuberculosis. Lancet 2000; 356: Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 200; 63: Pai M, Riley LW, Colford JM. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON- Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther 2005; 3: Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon- -based assay suing new antigens. Am J Respir Crit Care Med 2004; 70: Kobashi Y, Obase Y, Fukuda M, et al. Clinical reevaluation of the QuantiFERON -2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006; 43: Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 70: Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 74: American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 6:S2 S247 2 Detjen AK, Keil T, Hauer B, et al. Interferon- release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45: Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon- release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 75: Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV- infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 75: Chee CBE, KhinMar KW, Gan SH, et al. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 2007; 75: Berther FX, Rasmussen PB, Rosenkrands I, et al. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-0). Microbiology 998; 44: Renshaw PS, Panagiotidou P, Whelan A, et al. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-0 form a tight, : complex and characterization of the structural properties of ESAT-6, CFP-0, and the ESAT-6.CFP-0 complex. J Biol Chem 2002; 277: Original Research
ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationFactors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis
http://dx.doi.org/10.4046/trd.2012.72.5.416 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:416-425 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationPerformance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children
616 TUBERCULOSIS Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children T G Connell*, N Curtis*, S C Ranganathan, J P Buttery...
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationDiagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients
CLINICAL RESEARCH STUDY Diagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients Sung-Han Kim, MD, a,b,c Kyoung-Ho Song, MD, a Su-Jin Choi, MS, b Hong-Bin
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationEvaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationIndeterminate test results of T-SPOT TM.TB performed under routine field conditions
Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationReview. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis
Interferon- assays for tuberculosis diagnosis Review Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review Madhukar Pai, Lee W Riley, and John M Colford Jr A major challenge in
More informationKJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationLOW SENSITIVITY OF T-CELL BASED DETECTION OF TUBERCULOSIS AMONG HIV CO-INFECTED TANZANIAN IN-PATIENTS
442 EAST AFRICAN MEDICAL JOURNAL September 2008 East African Medical Journal Vol. 85 No. 9 September 2008 LOW SENSITIVITY OF T-CELL BASED DETECTION OF TUBERCULOSIS AMONG HIV CO-INFECTED TANZANIAN IN-PATIENTS
More informationKinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with tuberculous meningitis
ORIGINAL ARTICLE Korean J Intern Med 214;29:793-799 http://dx.doi.org/1.394/kjim.214.29.6.793 Kinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with
More informationImmediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2672 2676 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00482-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Immediate Incubation
More informationAnalysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy
Jpn. J. Infect. Dis., 64, 133-138, 2011 Original Article Analysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy Kiyoko Takayanagi, Misako Aoki, Kumiko
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationEffect of tuberculin skin testing on a Mycobacterium tuberculosisspecific
ERJ Express. Published on January 10, 2007 as doi: 10.1183/09031936.00117506 Effect of tuberculin skin testing on a Mycobacterium tuberculosisspecific IFN-γ assay Eliane M.S. Leyten 1, Corine Prins 1,
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationDiagnosis of Central Nervous System Tuberculosis by T-Cell-Based Assays on Peripheral Blood and Cerebrospinal Fluid Mononuclear Cells
CLINICAL AND VACCINE IMMUNOLOGY, Sept. 2008, p. 1356 1362 Vol. 15, No. 9 1556-6811/08/$08.00 0 doi:10.1128/cvi.00040-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Diagnosis
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
NDT Advance Access published January 22, 2009 Nephrol Dial Transplant (2009) 1 of 5 doi: 10.1093/ndt/gfn748 Original Article Interferon-gamma release assays versus tuberculin skin testing for detection
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationUsefulness of interferon-γ release assay for the diagnosis of sputum smear-negative pulmonary and extra-pulmonary TB in Zhejiang Province, China
Ji et al. Infectious Diseases of Poverty (2017) 6:121 DOI 10.1186/s40249-017-0331-1 RESEARCH ARTICLE Open Access Usefulness of interferon-γ release assay for the diagnosis of sputum smear-negative pulmonary
More informationSpecific Detection of Tuberculosis Infection An Interferon- based Assay Using New Antigens
Specific Detection of Tuberculosis Infection An Interferon- based Assay Using New Antigens Toru Mori, Mitsunori Sakatani, Fumio Yamagishi, Tetsuya Takashima, Yoshiko Kawabe, Keiji Nagao, Eriko Shigeto,
More informationDiagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)
Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs) Educational aims To provide an overview of interferon- release assays (IGRAs) used for detection of tuberculosis
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationReceived 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007
CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationClinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission Setting
Pulmonary Medicine Volume 2012, Article ID 757152, 6 pages doi:10.1155/2012/757152 Clinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission
More informationInterferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis
CLINICAL AUDIT Clinical Medicine 2013, Vol 13, No 4: 362 6 Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis Helen R Mujakperuo, Richard D Thompson and
More informationDiagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis
Clin. Lab. 2014;60:1865-1870 Copyright ORIGINAL ARTICLE Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis XUEQIONG WU 1, *, YUANZHENG MA 2, *, LAN WANG 1, DAWEI LI 2, YOURONG YANG 1,
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationWhat is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries?
REVIEW What is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries? Peter Daley & Poorvi Chordia Author for correspondence Department of Medicine Unit
More informationComparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts
Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts Inger Brock, Karin Weldingh, Troels Lillebaek, Frank Follmann, and Peter Andersen Department of Infectious Disease
More informationUse in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study Giovanni Ferrara, Monica Losi, Roberto D Amico, Pietro Roversi,
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationTime interval to conversion of interferon-c release assay after exposure to tuberculosis
Eur Respir J 2011; 37: 1447 1452 DOI: 10.1183/09031936.00089510 CopyrightßERS 2011 Time interval to conversion of interferon-c release assay after exposure to tuberculosis S.W. Lee*,#, D.K. Oh ", S.H.
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationSponsored document from The Journal of Infection
Sponsored document from The Journal of Infection Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice Sarah Gooding a,e, Oni Chowdhury a,e, Tim
More informationORIGINAL ARTICLE /j x. and 3 Department of Internal Medicine, University of Tor Vergata, Rome, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01391.x Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti 1,2, S. Carrara
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationDiagnostic Value of Elisa Serological Tests in Childhood Tuberculosis
Diagnostic Value of Elisa Serological Tests in Childhood Tuberculosis by R. Dayal, a G. Sirohi, a M. K. Singh, a P. P. Mathur, a B. M. Agarwal, a V. M. Katoch, b B. Joshi, b P. Singh, b and H. B. Singh
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTitle: Comparison of an ESAT-6/ CFP-10 Peptide-Based ELISPOT Assay to Tuberculin. Skin Test for Tuberculosis Screening in a Moderate Risk Population
CVI Accepts, published online ahead of print on 18 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationQuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
Jpn. J. Infect. Dis., 70, 502 506, 2017 Original Article QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients Thana Khawcharoenporn 1 *, Benjawan Phetsuksiri 2, Janisara
More informationTuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release assay
Eur Respir J 29; 34: 1423 1428 DOI: 1.1183/931936.5389 CopyrightßERS Journals Ltd 29 Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationUSE OF A T-CELL BASED TEST FOR DETECTION OF TB INFECTION AMONG IMMUNOCOMPROMISED PATIENTS
ERJ Express. Published on March 15, 2006 as doi: 10.1183/09031936.06.00110205 USE OF A T-CELL BASED TEST FOR DETECTION OF TB INFECTION AMONG IMMUNOCOMPROMISED PATIENTS Piana Federica 1-2, Codecasa Luigi
More informationImpact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
Journal of Infection (2007) 54, e169ee174 www.elsevierhealth.com/journals/jinf CASE REPORT Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
Nephrol Dial Transplant (2009) 24: 1952 1956 doi: 10.1093/ndt/gfn748 Advance Access publication 22 January 2009 Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis
More informationDiagnostic Microbiology and Infectious Disease
Diagnostic Microbiology and Infectious Disease 75 (3) 68 7 Contents lists available at SciVerse ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationThe Value of T-SPOT.TB Technology in the Diagnosis of Tuberculosis in Elderly Patients B Sun 1, L Ma 1, J Wu 1, H Kuang 1, L Zhao 1 ABSTRACT
The Value of T-SPOT.TB Technology in the Diagnosis of Tuberculosis in Elderly Patients B Sun 1, L Ma 1, J Wu 1, H Kuang 1, L Zhao 1 ABSTRACT Objectives: To investigate the clinical value of T-SPOT.TB technology
More informationThe tuberculin skin test (TST) was until recently the
Rapid diagnosis of Mycobacterium tuberculosis infection in children using interferon-gamma release assays (IGRAs) Shahla Riazi, M.D., 1,2 Barbara Zeligs, 1,2 Henry Yeager, M.D., 3 Stephen M. Peters, Ph.D.,
More informationThe tuberculin skin test (TST) was formerly the only. Review
Annals of Internal Medicine Review Systematic Review: T-Cell based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update Madhukar Pai, MD, PhD; Alice Zwerling, MSc; and Dick Menzies, MD,
More informationProspective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Apr. 2005, p. 491 496 Vol. 12, No. 4 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.4.491 496.2005 Copyright 2005, American Society for Microbiology. All Rights
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationThe Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017
The Diagnosis of Active TB Deborah McMahan, MD TB Intensive September 28, 2017 Agenda Epidemiology Big picture Conditions that Should Make You Suspicious Which test? Eeenie meenie miny mo Radiographic
More informationSilicotic subjects are at a high risk of. Comparison of T-Spot.TB and tuberculin skin test among silicotic patients
Eur Respir J 2008; 31: 266 272 DOI: 10.1183/09031936.00054707 CopyrightßERS Journals Ltd 2008 Comparison of T-Spot.TB and tuberculin skin test among silicotic patients C.C. Leung*, W.C. Yam #, W.W. Yew
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationIDSA GUIDELINE. Clinical Infectious Clinical Diseases Infectious Diseases Advance Access published December 8, 2016
Clinical Infectious Clinical Diseases Infectious Diseases Advance Access published December 8, 2016 IDSA GUIDELINE Official American Thoracic Society/Infectious Diseases Society of America/Centers for
More information